MARKET

PBYI

PBYI

Puma Biotec
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.59
+0.38
+3.72%
Closed 17:04 06/01 EDT
OPEN
10.30
PREV CLOSE
10.21
HIGH
10.73
LOW
9.91
VOLUME
908.22K
TURNOVER
--
52 WEEK HIGH
15.22
52 WEEK LOW
5.50
MARKET CAP
416.87M
P/E (TTM)
-4.9948
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 10 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PBYI stock price target is 12.50 with a high estimate of 16.00 and a low estimate of 6.00.

EPS

PBYI News

More
Edited Transcript of PBYI earnings conference call or presentation 7-May-20 8:30pm GMT
Q1 2020 Puma Biotechnology Inc Earnings Call
Thomson Reuters StreetEvents · 4d ago
Moving Average Crossover Alert: Puma Biotechnology
Zacks · 6d ago
Cantor Fitzgerald Maintains Neutral on Puma Biotechnology, Raises Price Target to $16
Cantor Fitzgerald maintains Puma Biotechnology (NASDAQ:PBYI) with a Neutral and raises the price target from $14 to $16.
Benzinga · 05/20 11:24
Puma Biotechnology: Still Bullish At These Prices
Seeking Alpha - Article · 05/14 19:14
Puma Biotechnology, Inc. (PBYI) Shares March Higher, Can It Continue?
Zacks · 05/14 14:42
New Strong Buy Stocks for May 13th
Zacks · 05/13 14:18
Puma's (PBYI) Earnings and Revenues Beat Estimates in Q1
Zacks · 05/11 17:01
Analysts Have Made A Financial Statement On Puma Biotechnology, Inc.'s (NASDAQ:PBYI) First-Quarter Report
Simply Wall St. · 05/11 13:12

Industry

Biotechnology & Medical Research
+0.07%
Pharmaceuticals & Medical Research
-0.77%

Hot Stocks

Symbol
Price
%Change

About PBYI

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib, oral), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.
More

Webull offers kinds of Puma Biotechnology Inc stock information, including NASDAQ:PBYI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PBYI stock news, and many more online research tools to help you make informed decisions.